title: Thrombocytopenic c-mpl(-/-) mice can produce a normal level of platelets after administration of 5-fluorouracil: the effect of age on the response.
abstract: Administration of 5-fluorouracil (5-FU) to mice results in a marked increase in the level of circulating platelets in 10 days. Mice lacking Mpl, the receptor for thrombopoietin (TPO), are thrombocytopenic. To gain insight into the mechanism by which 5-FU produces such a substantial stimulation of platelet production, this study investigated whether 5-FU (150 mg/kg) produced thrombocytosis in c-mpl(-/-) mice, thus establishing whether TPO was required for this response. A 5- to 6-fold increase in platelet levels in c-mpl(-/-) mice (to approximately 1000 x 10(9)/L) was observed on days 20 and 25 after 5-FU injection. Thus, at the peak of the response, c-mpl(-/-) mice had platelet levels comparable to those in normal mice. Administration of 5-FU also produced thrombocytosis in previously splenectomized c-mpl(-/-) mice. Comparison of the platelet response to 5-FU in young (6-12 weeks) and old (33-46 weeks) c-mpl(-/-) mice found that older mice produced a much more marked response than younger mice, with a mean maximum platelet level of approximately 1700 x 10(9)/L. To determine whether this increase in circulating platelets was preceded by an increase in hematopoietic progenitors, serial cultures of bone marrow and spleen were evaluated. A considerable increase in all colony types studied was observed on days 15 and 20 in spleens of c-mpl(-/-) mice, but no similar elevations were detected in bone marrow. These results indicate that c-mpl(-/-) mice can achieve a normal level of platelets after 5-FU injection, by means of a TPO-independent mechanism, and that they respond to 5-FU myelosuppression by producing large numbers of megakaryocytic, myeloid, and erythroid progenitors. (Blood. 2001;98:1019-1027)
authors.affiliation: INSERM U506, Hôpital Paul Brousse, Villejuif, France.
authors.forename: J
authors.initials: J
authors.lastname: Levin
authors.forename: L
authors.initials: L
authors.lastname: Cocault
authors.forename: C
authors.initials: C
authors.lastname: Demerens
authors.forename: C
authors.initials: C
authors.lastname: Challier
authors.forename: M
authors.initials: M
authors.lastname: Pauchard
authors.forename: J
authors.initials: J
authors.lastname: Caen
authors.forename: M
authors.initials: M
authors.lastname: Souyri
mesh_terms: D000367:Age Factors; D000818:Animals; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects*; D001854:Bone Marrow Cells; D004195:Disease Models, Animal; D005472:Fluorouracil / Q000008:administration & dosage / Q000494:pharmacology*; D008533:Megakaryocytes / Q000648:ultrastructure; D051379:Mice; D018345:Mice, Knockout; D009363:Neoplasm Proteins; D010976:Platelet Count; D011003:Ploidies; D011518:Proto-Oncogene Proteins / Q000172:deficiency / Q000235:genetics; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; D013154:Spleen / Q000166:cytology; D013156:Splenectomy; D013234:Stem Cells / Q000166:cytology; D013921:Thrombocytopenia / Q000097:blood / Q000188:drug therapy* / Q000235:genetics
chemical_list: D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; C082218:MPL protein, human; D005472:Fluorouracil